Daito Pharmaceutical Co (TSE:4577) Cyclically Adjusted Revenue per Share: 円1,677.01 (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4577 Daito Pharmaceutical Co Ltd TSE:4577
80 GF Score
Price 円1,314.00
GF Value 円1,288.80
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Daito Pharmaceutical Co Cyclically Adjusted Revenue per Share?

Daito Pharmaceutical Co TSE:4577 -0.68% 80 Cyclically Adjusted Revenue per Share is 円1,677.01 as of May. 2026. GuruFocus rates TSE:4577 with a GF Score™ of 80/100 and a GF Value™ of 円1,288.80 (Fairly Valued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Daito Pharmaceutical Co's adjusted revenue per share for the three months ended in May. 2026 was 円473.176. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円1,677.01 for the trailing ten years ended in May. 2026.

During the past 12 months, Daito Pharmaceutical Co's average Cyclically Adjusted Revenue Growth Rate was 2.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 3.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Daito Pharmaceutical Co was 4.00% per year. The lowest was 2.80% per year. And the median was 3.55% per year.

As of today (2026-09-04), Daito Pharmaceutical Co's current stock price is 円1314.00. Daito Pharmaceutical Co's Cyclically Adjusted Revenue per Share for the quarter that ended in May. 2026 was 円1,677.01. Daito Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is 0.78.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Daito Pharmaceutical Co was 1.48. The lowest was 0.60. And the median was 0.80.


Daito Pharmaceutical Co  (TSE:4577) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Daito Pharmaceutical Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1314.00/1677.01
=0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Daito Pharmaceutical Co was 1.48. The lowest was 0.60. And the median was 0.80.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Daito Pharmaceutical Co Cyclically Adjusted Revenue per Share Related Terms


Daito Pharmaceutical Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Daito Pharmaceutical Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Daito Pharmaceutical Co Cyclically Adjusted Revenue per Share Chart

Daito Pharmaceutical Co Annual Data
Trend May17 May18 May19 May20 May21 May22 May23 May24 May25 May26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,452.44 1,501.24 1,555.86 1,633.16 1,677.01

Daito Pharmaceutical Co Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,633.16 1,644.85 1,661.47 1,649.71 1,677.01

TSE:4577 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Daito Pharmaceutical Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daito Pharmaceutical Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daito Pharmaceutical Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Daito Pharmaceutical Co's Cyclically Adjusted PS Ratio falls into.


TSE:4577
80GF Score
Daito Pharmaceutical Co Ltd TSE:4577
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Daito Pharmaceutical Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Daito Pharmaceutical Co's adjusted Revenue per Share data for the three months ended in May. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of May. 2026 (Change)*Current CPI (May. 2026)
=473.176/113.5000*113.5000
=473.176

Current CPI (May. 2026) = 113.5000.

Daito Pharmaceutical Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201608 330.949 97.900 383.684
201611 367.218 98.600 422.710
201702 315.993 98.100 365.598
201705 365.110 98.600 420.284
201708 351.700 98.500 405.258
201711 391.329 99.100 448.192
201802 333.529 99.500 380.458
201805 372.136 99.300 425.352
201808 353.761 99.800 402.323
201811 378.055 100.000 429.092
201902 372.547 99.700 424.113
201905 389.841 100.000 442.470
201908 423.522 100.000 480.697
201911 416.467 100.500 470.338
202002 392.580 100.300 444.246
202005 366.062 100.100 415.065
202008 462.377 100.100 524.274
202011 408.769 99.500 466.284
202102 391.178 99.800 444.877
202105 360.300 99.400 411.409
202108 389.340 99.700 443.231
202111 352.475 100.100 399.659
202202 359.952 100.700 405.706
202205 314.341 101.800 350.469
202208 380.178 102.700 420.158
202211 357.242 103.900 390.250
202302 354.458 104.000 386.836
202305 333.101 105.100 359.724
202308 385.331 105.900 412.985
202311 377.511 106.900 400.819
202402 336.158 106.900 356.912
202405 395.608 108.100 415.370
202408 414.598 109.100 431.319
202411 389.263 110.000 401.649
202502 393.901 110.800 403.500
202505 461.326 111.800 468.341
202508 434.453 112.100 439.879
202511 406.501 113.200 407.578
202602 391.297 112.200 395.831
202605 473.176 113.500 473.176

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円1,677.01 mean?
Daito Pharmaceutical Co (TSE:4577) has a Cyclically Adjusted Revenue per Share of 円1,677.01 as of May. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Daito Pharmaceutical Co and its competitors.
Is Daito Pharmaceutical Co's Cyclically Adjusted Revenue per Share too high?
Daito Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円1,677.01. Overall, Daito Pharmaceutical Co has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Daito Pharmaceutical Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Daito Pharmaceutical Co's Cyclically Adjusted Revenue per Share of 円1,677.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Daito Pharmaceutical Co and its competitors. Daito Pharmaceutical Co's current Cyclically Adjusted Revenue per Share is 円1,677.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daito Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Daito Pharmaceutical Co (TSE:4577) is currently considered Fairly Valued. The stock's GF Value™ is 円1,288.80, compared to a current price of 円1,314.00 — trading 2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円1,677.01. Daito Pharmaceutical Co's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Daito Pharmaceutical Co (TSE:4577), the current Cyclically Adjusted Revenue per Share is 円1,677.01 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Daito Pharmaceutical Co (TSE:4577) Overvalued in 2026?

Based on GuruFocus' analysis, Daito Pharmaceutical Co stock appears to be overvalued. The current stock price of 円1,314.00 is trading 2% above its estimated GF Value™ of 円1,288.80. GuruFocus considers Daito Pharmaceutical Co to be Fairly Valued.

Key valuation signals for TSE:4577:

  • Cyclically Adjusted Revenue per Share: 円1,677.01
  • GF Value™: 円1,288.80 vs. price of 円1,314.00 (2% above fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the TSE:4577 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Daito Pharmaceutical Co Business Description

Address 326 Yokamachi, Toyama, JPN, 939-8567
Daito Pharmaceutical Co Ltd is engaged in the research and development of pharmaceutical products. The company also undertakes contract manufacturing.
80GF Score

Get the complete analysis for TSE:4577

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,314.00
Price
円1,288.80
GF Value